Cytosorbents Corp CTSO Income Statement

Cytosorbents corp (CTSO)

Income statement / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Sep'11	Jun'11	Sep'10	Jun'10
Revenue:
CytoSorb sales
-	-	-	5,850	-	-	-	5,187	4,403	-	3,416	3,027	2,596	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other sales
-	-	-	0	-	-	-	58	29	-	32	14	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total revenue
8,707	7,812	6,095	5,850	5,191	7,082	5,742	5,245	4,433	-	3,448	3,041	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Grant income
-	-	-	382	-	-	-	509	491	-	375	525	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Product Sales
-	-	-	-	-	-	-	-	-	-	-	-	2,596	-	2,143	1,852	1,597	1,495	1,071	773	703	871	1,031	663	569	314	203	127	176	87	13	33	16	0	-	-	-
Grant income
-	-	-	-	-	-	-	-	-	-	-	-	517	-	268	369	212	265	272	179	18	0	128	358	491	565	677	163	195	516	591	50	33	0	-	-	-
Other revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0	0	11	0	2	2	2	1	0	0	0	0	-	-	-	-	-	-	-	-
Total revenue
-	-	-	-	-	-	-	-	-	-	-	-	3,113	-	2,411	2,222	1,810	1,760	1,343	963	723	873	1,162	1,024	1,062	879	880	291	371	604	605	83	50	0	-	-	-
Total revenue
-	-	-	6,232	-	-	-	5,755	4,924	-	3,824	3,566	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Cost of revenue
2,384	2,094	1,696	1,834	1,738	2,083	2,052	1,785	1,567	-	1,516	1,482	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of revenue
-	-	-	-	-	-	-	-	-	-	-	-	1,254	-	963	873	819	803	638	465	304	329	475	666	662	837	620	199	253	113	141	10	53	0	-	-	-
Gross margin
6,322	5,335	4,398	4,398	3,453	3,997	3,690	3,969	3,357	3,381	2,307	2,084	1,859	1,786	1,447	1,349	990	957	704	498	418	544	686	358	399	41	260	91	117	490	463	72	-3	0	-	-	-
Other expenses:
Research and development
1,965	3,558	3,185	2,929	2,418	2,478	1,943	1,575	1,725	1,650	643	458	469	952	1,172	1,092	856	1,252	866	801	951	967	880	346	236	32	294	708	704	629	554	715	632	779	854	526	352
Legal, financial and other consulting
519	575	733	592	561	711	416	457	416	378	238	443	279	331	279	319	254	286	288	297	215	445	49	165	236	338	157	189	222	241	150	73	161	93	67	42	127
Selling, general and administrative
6,316	6,633	6,107	4,506	4,758	6,393	4,040	6,123	4,316	5,158	3,574	3,513	2,667	5,072	2,140	2,625	1,970	2,080	1,700	1,626	1,515	2,023	1,240	1,208	1,080	674	687	600	613	432	359	293	269	352	-	-	-
General and administrative
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	191	212	194
Change in fair value of management and incentive units
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	-	-	-
Total expenses
8,801	10,766	10,026	8,028	7,738	9,582	6,400	8,157	6,458	7,186	4,456	4,415	3,416	6,356	3,592	4,036	3,080	3,619	2,855	2,725	2,681	3,436	2,170	1,721	1,553	1,045	1,139	1,498	1,540	1,303	1,064	1,082	1,063	1,225	1,114	780	674
Loss from operations
-2,478	-5,431	-5,627	-3,629	-4,285	-5,585	-2,710	-4,187	-3,101	-3,805	-2,149	-2,330	-1,557	-4,570	-2,144	-2,687	-2,090	-2,662	-2,150	-2,227	-2,263	-2,891	-1,483	-1,363	-1,154	-1,004	-879	-1,406	-1,422	-812	-601	-1,009	-1,067	-1,225	-	-	-
Other expense:
Gain on disposal of property and equipment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	-	-	-
Gain on extinguishment of debt
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	-	-	-
Interest expense, net
-305	-311	-301	-214	-205	-196	-185	-839	-239	-251	-253	-123	-120	-119	-117	1	3	0	3	3	2	1	-46	-127	-137	-123	-84	-8	-206	-116	-50	-37	-359	-503	-227	-7	-1
Loss on foreign currency transactions
-668	701	-955	297	-393	-240	-108	-793	358	232	348	719	153	-534	73	-128	231	-191	70	61	-448	-	-202	-19	-	-	-	-	-	-	-	-	-	-	-	-	-
Penalties associated with non-registration of Series A Preferred Stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	-	-	-
Change in warrant liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	190	-18	-	771	-3,596	2,007	2,326	-234	342	-316	0	0	0	0	-	-	-	-	-	-	-	-
Total other expense, net
-974	389	-1,257	82	-598	-437	-294	-1,633	119	-18	94	596	32	-481	-43	-317	253	-1,008	-697	3,661	-2,453	-2,488	-14	-490	179	-123	-84	-8	-206	-116	-50	-37	-359	-503	-227	-7	-1
Loss before benefit from income taxes
-3,452	-5,041	-6,885	-3,547	-4,883	-6,022	-3,004	-5,821	-2,982	-3,823	-2,054	-1,734	-1,524	-5,052	-2,188	-3,005	-1,836	-3,671	-2,847	1,434	-4,716	-5,380	-1,498	-1,853	-975	-1,127	-964	-1,414	-1,628	-929	-651	-1,047	-1,426	-1,728	-1,341	-788	-676
Benefit from income taxes
0	-1,092	0	0	0	-619	0	0	0	-676	0	0	0	-318	0	0	0	-324	0	0	0	-385	0	0	0	-458	0	0	0	-391	0	0	0	0	-	-	-
Dividend, warrant exercise price adjustment
-	-	-	-	-	-	-	-	-	-	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Preferred stock dividends
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5,496	1,281	1,374	1,114	667	525	616	586	640	629	577	663	734	877	401	413
Net loss attributable to common shareholders
-3,452	-3,949	-6,885	-3,547	-4,883	-5,403	-3,004	-5,821	-2,982	-3,482	-2,054	-1,734	-1,524	-4,733	-2,188	-3,005	-1,836	-	-	-	-4,716	-10,491	-2,779	-3,227	-2,089	-1,336	-1,489	-2,031	-2,215	-1,178	-1,281	-1,624	-2,090	-2,463	-2,219	-1,190	-1,089
Basic and diluted net loss per common share
-0.10	-0.13	-0.21	-0.11	-0.15	-0.17	-0.10	-0.19	-0.10	-0.13	-0.07	-0.06	-0.06	-0.18	-0.09	-0.12	-0.07	-	-0.11	-	-0.19	-	-0.22	-	-0.20	-0.72	-0.01	-0.01	-0.01	0.00	-0.01	-0.01	-0.01	-0.01	-0.01	-0.01	-0.01
Weighted average number of shares of common stock outstanding
33,981	32,457	32,365	32,266	31,931	31,917	31,305	30,302	29,351	28,791	28,206	27,953	25,503	25,473	25,444	25,416	25,401	-	25,037	-	24,394	-	12,496	-	10,619	-659,301	242,512	231,583	222,968	212,883	204,438	194,439	181,150	168,230	-	-	-
Net loss
-3,452	-3,949	-6,885	-3,547	-4,883	-5,403	-3,004	-5,821	-2,982	-3,147	-2,054	-1,734	-1,524	-4,733	-2,188	-3,005	-1,836	-3,346	-2,847	1,434	-4,716	-4,994	-1,498	-1,853	-975	-669	-964	-1,414	-1,628	-537	-651	-1,047	-1,426	-1,728	-1,341	-788	-676
Comprehensive loss:
Basic
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.06	-	-	-	-0.27	-	-	-	-	-	-	-	-	-	-	-	-	-
Diluted
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.05	-	-	-	-0.27	-	-	-	-	-	-	-	-	-	-	-	-	-
Basic
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	24,768	-	-	-	12,047	-	-	-	-	-	-	-	-	-	-	-	-	-
Diluted
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	28,826	-	-	-	12,047	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss
-3,452	-3,949	-6,885	-3,547	-4,883	-5,403	-3,004	-5,821	-2,982	-3,147	-2,054	-1,734	-1,524	-4,733	-2,188	-3,005	-1,836	-3,346	-2,847	1,434	-4,716	-4,994	-1,498	-1,853	-975	-669	-964	-1,414	-1,628	-537	-651	-1,047	-1,426	-1,728	-1,341	-788	-676
Other comprehensive income (loss):
Currency translation adjustment
609	-630	811	-249	306	218	99	661	-329	-237	-280	-610	-131	475	-60	144	-245	138	-49	-76	344	160	118	4	0	-80	40	-0	-2	-12	0	0	0	-	-	-	-
Comprehensive loss
-2,842	-4,579	-6,073	-3,797	-4,577	-5,185	-2,905	-5,159	-3,311	-3,384	-2,334	-2,344	-1,656	-4,257	-2,248	-2,860	-2,081	-3,208	-2,897	1,357	-4,372	-4,834	-1,380	-1,849	-974	-749	-924	-1,415	-1,631	-550	-651	-1,047	-1,426	-	-	-	-
Weighted average number of shares of common stock outstanding
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	159,137	106,250	95,409
Product
Total revenue
8,155	-	5,728	-	4,576	-	5,102	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cyto Sorb Sales
Total revenue
8,155	-	5,648	-	4,509	-	5,102	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Sales
Total revenue
0	-	80	-	66	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Grant
Total revenue
551	-	366	-	615	-	640	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-